The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial
John G.F. Cleland(Imperial College London), Theis Lange(Aalborg University), Arantxa González(Instituto de Salud Carlos III), Kenneth McDonald(University College Dublin), Johannes Petutschnigg(German Centre for Cardiovascular Research), Nicolas Girerd(Inserm), Frank Edelmann(Deutsches Herzzentrum der Charité), Burkert Pieske(German Centre for Cardiovascular Research), Patrick Rossignol(Inserm), Roberto Latini(Mario Negri Institute for Pharmacological Research), Lars Køber(University of Copenhagen), Philippe Rouet(Université Toulouse III - Paul Sabatier), Faı̈ez Zannad(Inserm), Pierpaolo Pellicori(Glasgow Royal Infirmary), Jan A. Staessen, Beatrice Mariottoni(Azienda Usl 8 Arezzo), Mamas A. Mamas(Royal Stoke University Hospital), Hans‐Peter Brunner‐La Rocca(Inserm), Mark R. Hazebroek(Maastricht University), Anne Pizard(Inserm), Stéphane Heymans(Maastricht University), Javier Dı́ez(Universidad de Navarra), Timothy Collier(London School of Hygiene & Tropical Medicine), Stéphanie Grojean(Centre de Médecine Préventive), Fozia Ahmed(Manchester Academic Health Science Centre), Dan Atar, Muhammad Javed Khan(Glasgow Royal Infirmary), João Pedro Ferreira(Inserm), Kenneth Dickstein, Andrew L. Clark(University of Hull), Joe Cuthbert(University of Hull), Blerim Mujaj(University Medical Center Freiburg), Franco Cosmi(Inserm), Job A.J. Verdonschot(Maastricht University Medical Centre)
Cited by 143
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k